Goldman Sachs Group Inc. Buys 111,611 Shares of Repligen Corporation (NASDAQ:RGEN)

Goldman Sachs Group Inc. boosted its stake in Repligen Corporation (NASDAQ:RGEN) by 76.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 258,287 shares of the biotechnology company’s stock after purchasing an additional 111,611 shares during the period. Goldman Sachs Group Inc. owned about 0.69% of Repligen Corporation worth $10,704,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new stake in Repligen Corporation in the 1st quarter valued at approximately $103,000. Victory Capital Management Inc. increased its holdings in Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 1,475 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Repligen Corporation in the 2nd quarter valued at approximately $120,000. Oppenheimer Asset Management Inc. acquired a new stake in Repligen Corporation in the 2nd quarter valued at approximately $123,000. Finally, JPMorgan Chase & Co. increased its holdings in Repligen Corporation by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 908 shares during the last quarter. Hedge funds and other institutional investors own 96.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/goldman-sachs-group-inc-purchases-111611-shares-of-repligen-corporation-rgen.html.

RGEN has been the subject of several research reports. TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Saturday, August 12th. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 target price on shares of Repligen Corporation in a report on Thursday, October 19th. Finally, William Blair started coverage on shares of Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $45.40.

Repligen Corporation (NASDAQ RGEN) traded up 1.33% during trading on Friday, hitting $38.12. 302,398 shares of the company’s stock traded hands. The stock has a market cap of $1.42 billion, a P/E ratio of 74.60 and a beta of 1.18. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81. The firm’s 50-day moving average price is $40.03 and its 200 day moving average price is $39.88.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 earnings per share. Analysts anticipate that Repligen Corporation will post $0.59 earnings per share for the current fiscal year.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply